Using Tamsulosin to treat children with Posterior Urethral Valve
Official title: Efficacy and Safety of Tamsulosin, a Selective Alpha-1 Adrenergic Blocker, for Children with Posterior Urethral Valve: a Randomized Controlled Trial
Run by Mansoura University · NCT06737016 · Data updated 2026-11-12
This study is testing if the medication Tamsulosin can help children with Posterior Urethral Valve feel better and reduce urinary problems after their treatment.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | Any age to 12 Years |
| Sex | Men only |
| Enrollment | 50 (estimated) |
| Sponsor | Mansoura University Academic / other |
| Locations | 1 site (Al Mansurah, Dakahlia Governorate) |
| Status | Recruiting |
| Started | November 1, 2024 |
| Main results expected | May 2026 |
| Study ends | November 2026 |
| Registry record updated | December 20, 2024 |
| Trial ID | NCT06737016 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are children diagnosed with Posterior Urethral Valve.
✕Probably not a fit
Patients with other urinary tract conditions or those who have undergone urinary diversion procedures may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study evaluates the safety and efficacy of Tamsulosin, an alpha-1 adrenergic blocker, in children diagnosed with Posterior Urethral Valve (PUV) following valve ablation. The research focuses on assessing improvements in upper urinary tract conditions, bladder outlet resistance, and the recurrence of urinary tract infections. Participants will receive Tamsulosin along with other medications like Oxybutynin and Trimethoprim/sulfamethoxazole to monitor their effects. The study aims to provide insights into the potential benefits and side effects of this treatment approach.
Why it matters
Potential benefit: If successful, this treatment could improve urinary function and reduce complications in children with Posterior Urethral Valve.
How similar studies have gone: While the use of Tamsulosin in adults has shown promise, this specific application in children with PUV is novel and has not been extensively tested.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Children with a diagnosis of PUV. Exclusion Criteria: 1. Patients with other conditions that can potentially affect lower or upper urinary tract functions (e.g. spinal dysraphism, anorectal malformation and prune belly syndrome) 2. Patients who were treated with urinary diversion as vesicostomy or cutaneous ureterostomy. 3. Patients who had primary treatment of PUV ablation at other hospitals. 4. Contraindications to α blocker treatment. 5. Patients who refuse to participate in the study
Where it's running
-
Mansoura Urology and Nephrology Center
Al Mansurah, Dakahlia Governorate, Egypt Recruiting
Study contacts
- Principal investigator: Mohamed Hussiny — urology and nephrology center mansoura university
- Study coordinator: Mohamed Hussiny
- Email: mohamedhussiny1@yahoo.com
- Phone: +201064156383
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Assessing quality of life in children with posterior urethral valves
This study looks at how being treated for posterior urethral valves affects the quality of life for boys aged 6 to 17, focusing on their kidney health and daily living.
-
Transplanting both a kidney and a bladder at the same time
This study is testing if it's possible to safely transplant both a kidney and a bladder at the same time in patients who have kidney problems caused by bladder issues.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.